ClinicalTrials.gg
Status unknownNCT05021770Updated Aug 26, 2021

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

A Phase 1/2 interventional study of Orelabrutinib and Orelabrutinib in Refractory and Relapsed Primary CNS Lymphoma, PCNSL and Non Hodgkin Lymphoma, sponsored by Huiqiang Huang. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-26.

Sponsored by Huiqiang Huang · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
124th of 183
29 · median 58
Started
2021
with 19 others
Phase 1/2
42 of 196
27 open now
Registered
94th of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 124th largest by planned enrollment of the 183 interventional ones that give a count, is one of 20 that started in 2021, is one of 42 in phase 1/2, and was the 94th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to investigate the maximum tolerated dose and efficacy of Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous system lymphoma (PCNSL).

03

Conditions studied

  • Refractory and Relapsed Primary CNS Lymphoma
  • PCNSL
  • Non Hodgkin Lymphoma

Keywords

  • PCNSL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and woman who aged 18 or older on the day of consenting to the study.
  2. Participants must be able to understand and willing to sign a written document.
  3. performance status of 0 to 2.
  4. documented primary central nervous system(CNS) lymphoma.
  5. Participants should have evidence of 1 measurable or evaluable enhancing disease on MRI, PET-CT or PET-MRI.
  6. disease with at least 1 prior HD-MTX-based therapy.
  7. of > 3 months (in the opinion of the investigator).
  8. Any non-hematologic toxicity associated with prior treatment should be stable and recovered to ≤ Grade 1 (according to V5.0,except for alopecia)
  9. Demonstrate adequate organ function as defined below: (all screening labs should be performed within 14 days of treatment initiation)

    • (ANC) ≥ 1.0 x 10\^9/L, ≥ 75 x 10\^9/L, ≥80 g/L;
    • (INR) and activated partial thromboplastin time (APTT) ≤1.5 times the ;
    • (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal;
    • Serum ≤ 1.5 times the upper limit of normal;
    • ≥ 60 mL/min calculated by the Cockcroft-Gault formula using actual body weight.
  10. Must be able to tolerate MRI/CT/PET-CT/PET-MRI scans and lumbar puncture.
  11. Ability to swallow oral medications.
  12. Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
  13. If the disease progresses after radiotherapy, there is no need for ;If the tumor responds after radiotherapy, a 6-month washout period is required.
  14. treatment with thiotepa-containing regimens is effective, and patients who relapse after more than 1 year can be enrolled.

Exclusion criteria

Exclusion Criteria:

  1. The pathological diagnosis was T-cell lymphoma.
  2. Prior therapy with a or BTK inhibitor.
  3. Participation in another clinical study with an product during the 12 weeks prior to the first day of study treatment.
  4. Participants requires more than 5 mg of dexamethasone daily or the equivalent for control of primary CNS symptoms lasting for more than 5 days within 14 days.
  5. Active bleeding within 4 weeks prior to first administration, or ongoing use of anticoagulant/antiplatelet agents, or tendency to bleeding (e.g., esophageal varices at risk for bleeding, locally active ulcerative lesions) or coagulation disorder as considered by the investigator.
  6. Has an uncontrolled or significant cardiovascular disease, including (but not limited to) :

    • Any of the following conditions within 6 months prior to initial administration: congestive heart failure ( class III or IV), myocardial infarction, unstable angina, or arrhythmia requiring treatment at the time of screening, (LVEF) \<50%;
    • Primary or secondary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmic right ventricular cardiomyopathy, restricted cardiomyopathy, undefined cardiomyopathy);
    • Clinical history of prolonged phase, grade II type II atrioventricular block or grade III atrioventricular block or QTc interval (F method) \& GT;470 msec (female) or >;480msec (male).
    • Hypertension, which is difficult to control, is not suitable for this study
  7. Uncontrolled infections or infections requiring intravenous antimicrobial treatment.
  8. Known active infection with virus (HCV), virus (HBV) or syphilis as determined by serologic tests and/or PCR.
  9. History of or positive (HIV) screen result.
  10. Patient underwent major systemic surgery ≤ 6 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug.
  11. Previous organ transplantation or stem cell transplantation.
  12. Pregnant or lactating women, or subjects of childbearing age who do not want to use for 180 days from the study period to the end of the study.
  13. History of stroke and intracranial hemorrhage within 6 months before the first administration, except intracranial hemorrhage caused by surgical sequelae.
  14. Patient with hepatic、renal 、neurological、psychiatric, or endocrine disease , as Investigator's discretion, is too damaged to participate in this study; Patient having other conditions that should exclude it from the trial, as the Investigator's discretion.
  15. Alcohol or drug abuse.
  16. Allergic to any component of the investigational product.
  17. Participants who received live viral vaccination within 4 weeks from enrollment date. Patients are prohibited from receiving , including influenza vaccines, during the study period.
  18. Previous CAR-T therapy.
  19. PVRL.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    Phase Ib

    Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined with thiotepa, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 200mg will be used for phase II trial (RP2D). Orelabrutinib: 150mg or 200mg orally daily. Thiotepa: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle).

    Drug: Orelabrutinib · Drug: Thiotepa

  • Experimental
    Phase II

    Participants will receive orelabrutinib and thiotepa at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles. Orelabrutinib: RP2D (150 mg or 200 mg qd) Thiotepa:Sintilimab: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle).

    Drug: Orelabrutinib · Drug: Thiotepa

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 Dose Escalation:The maximum tolerated dose (MTD)

    To determine the maximum tolerated dose (MTD)

    Time frame: Incidence of dose limiting toxicities (DLTs) up to 21 days

  2. Part 2 Dose Expansion:ORR (Investigator-Assessed)

    The overall response rate (ORR) including complete response (CR), unconfirmed complete (CRu) and partial response (PR) according to the 2005 Response Criteria of the International Primary CNS Lymphoma Collaborative Group (IPCG)

    Time frame: Up to 2 years

Secondary outcomes

  1. Part 1 Dose Escalation:Objective response rate (ORR)

    The objective response rate (ORR) is defined as the proportion of patients with a best response of CR, CRu or PR

    Time frame: Up to 2 years

  2. Part 1 Dose Escalation:Compelet response rate (CRR)

    The complete response rate (ORR) is defined as the proportion of patients with a best response of CR or CRu

    Time frame: Up to 2 years

  3. Part 1 Dose Escalation:Duration of overall response (DOR)

    The duration of overall response is measured from the time measurement

    Time frame: Up to 2 years

  4. Part 1 Dose Escalation:Disease control rate (DCR)

    The disease control rate (DCR) is defined as the proportion of patients with a best response of CR, CRu, PR or SD

    Time frame: Up to 2 years

  5. Part 1 Dose Escalation:Progression-free survival (PFS)

    The progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first

    Time frame: Up to 2 years

  6. Part 1 Dose Escalation:Overall survival (OS)

    The overall survival (OS) is defined as the duration of time from start of treatment to time of death.

    Time frame: Up to 2 years

  7. Part 2 Dose Expansion:Compelet response rate (CRR)

    The complete response rate (ORR) is defined as the proportion of patients with a best response of CR or CRu

    Time frame: Up to 2 years

  8. Part 2 Dose Expansion:Duration of overall response (DOR)

    The duration of overall response is measured from the time measurement

    Time frame: Up to 2 years

  9. Part 2 Dose Expansion:Disease control rate (DCR)

    The disease control rate (DCR) is defined as the proportion of patients with a best response of CR, CRu, PR or SD

    Time frame: Up to 2 years

  10. Part 2 Dose Expansion:Progression-free survival (PFS)

    The progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first

    Time frame: Up to 2 years

  11. Part 2 Dose Expansion:Overall survival (OS)

    The overall survival (OS) is defined as the duration of time from start of treatment to time of death.

    Time frame: Up to 2 years

  12. The toxicity profile of the orelabrutinib and thiotepa combination therapy

    All subjects who received at least one dose of OT will be included in the safety analysis. Adverse events will be graded by the investigator according to the NCI-CTCAE Version 5.0.

    Time frame: Up to 2 years

Other outcomes

  1. Describe the tumor mutation profile by NGS

    DNA from tumor tissue and CSF will be sequencing by next generation sequencing (NGS).Identify the PNCSL-related variants and gene expression alterations by NGS.

    Time frame: Up to 2 years

07

Study locations

1 site
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    • Huiqiang Huang, Professor · Contacthuanghq@sysucc.org.cn · +86 020 87343350
    • Huiqiang Huang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2021; primary completion for Dec 2022, 12 months later.

Of 66 non-industry phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 110. This study's planned 12 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2021
First posted
Aug 26, 2021
StartEst.
Dec 2021
Primary completionEst.
Dec 2022
CompletionEst.
Jun 2024
Last update
Aug 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05021770
Lead sponsor
Huiqiang Huang
Collaborators
Guangdong 999 Brain Hospital
Responsible party
Huiqiang Huang (Professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Aug 26, 2021
Start date
Dec 2021 (estimated)
Primary completion
Dec 2022 (estimated)
Completion
Jun 2024 (estimated)
Last update
Aug 26, 2021

Study contacts

Huiqiang Huang, Professor
Contact
huanghq@sysucc.org.cn
+86 020 87343350

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion